Evidence for use of urinary LAM

Slides:



Advertisements
Similar presentations
Exploring Synergies Health Systems and Sustainability TB/HIV collaboration Alasdair Reid UNAIDS Pretoria International Multistakeholder Consultation on.
Advertisements

HIV and Tuberculosis interaction and integration Anthony D Harries The “Union”, Paris, France London School of Hygiene & Tropical Medicine, UK.
CHER Trial: Early Antiretroviral Therapy and Mortality Among HIV- Infected Infants New England J Med 2008;359 (21):
Cost-effectiveness of ART and the Three I’s for HIV/TB to prevent tuberculosis among people living with HIV Somya Gupta, Taiwo Abimbola, Anand Date, Amitabh.
CDC Recommendations for HIV Testing of Adults and Adolescents Christina Price, MPH Delta Region AIDS Education and Training Center.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
12 June 2004Clinical algorithms in public health1 Seminar on “Intelligent data analysis and data mining – Application in medicine” Research on poisonings.
Living with HIV, Dying of TB Intensified TB case finding among people living with HIV Adapted from presentation by Colleen Daniels TB/HIV Advocacy Stop.
Systematic TB Screening: Philippine Experience The 9th Technical Advisory Group and National TB Program Mangers meeting for TB control in the Western Pacific.
Washington D.C., USA, July 2012www.aids2012.org The value of universal TB screening with GeneXpert MTB/RIF in pre-ART patients in Harare L. Mupfumi.
Graeme Meintjes Department of Medicine, University of Cape Town HIV Service, GF Jooste Hospital TB-IRIS Research priorities and update from Kampala workshop.
In the name of God Fariba Rezaeetalab Assistant Professor.
The ninth Technical Advisory Group and National TB Managers meeting
Annabel Baddeley Global TB Programme WHO, Geneva
Moving forward in the diagnosis of infectious diseases in developing countries: a focus on malaria Forum organized by Fondation Mérieux & the Roll Back.
Sensitivity, specificity and predictive values of symptoms to detect tuberculosis in the ZAMSTAR community based prevalence studies Peter Godfrey-Faussett.
Unit 5: IPT Isoniazid TB Preventive Therapy
Standard of Care for MDR-TB
Cost-Conscious Care Presentation Follow-up Chest X-Ray in Patients Admitted for Community Acquired Pneumonia Huy Tran, PGY-2 12/12/2013.
Reduced treatment delays for drug-resistant TB/HIV co-infected patients with decentralised care and rapid Xpert MTB/Rif test in Khayelitsha, South Africa.
Eight Week Randomized Trial of Treatment with Pa-824, Moxifloxacin, and Pyrazinamide in Drug Sensitive and Multi-Drug Resistant Tuberculosis July 21, 2014.
Matthew Fox Center for Global Health & Development Department of Epidemiology Boston University July 17, 2011 The first step is admitting you have a problem.
Cost-Effectiveness of a Lateral-Flow Urine Lipoarabinomannan Test for TB diagnosis in HIV-infected South African Adults Di Sun1; Susan Dorman2,3,4; Maunank.
A decentralized model of care for drug-resistant tuberculosis in a high HIV prevalence setting Cheryl McDermid, Helen Cox, Simiso Sokhela, Gilles van Cutsem,
Challenges of service integration: the TB model Linda-Gail Bekker The Desmond Tutu HIV Centre, Faculty of Health Sciences, University of Cape Town, South.
Johns Hopkins Center for Tuberculosis Research
Tuberculosis Research of INA-RESPOND on Drug-resistant
ICF commentary New York TAG core group. Systems –Lab resources – how available are culture facilities? –Human resources – how many staff are needed? Contamination.
Dr. Hind E. Satti Partners In Health, Lesotho March, 2008.
Revision of new diagnostics for TB
High cost of Xpert MTB/RIF ® testing per tuberculosis case diagnosed at Partners in Hope Medical Center, a public private HIV care clinic in Lilongwe,
Washington D.C., USA, July 2012www.aids2012.org Implementing Xpert ® MTB/RIF in Rural Zimbabwe Impact on diagnosis of smear-negative TB and time-
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
Integration of TB and HIV Screening, Care and Treatment in Mulago Hospital, Uganda Rhoda Wanyenze, Doris Mwesigire, Henry Luzze, Violet Gwokyalya, Julius.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Intermittent vs Continuous Pulse Oximetry McCulloh R, Koster M, Ralston S, et al.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Yield and impact of repeated screening for tuberculosis and isoniazid preventive therapy among patients.
Early TB case detection in pre-trial detention centers (SIZOs) and prison colonies in Ukraine 46 th Union World Conference on Lung Health Cape Town, South.
Dr Justin O’Grady. Zambia is a high burden TB and high HIV setting 44,154 TB cases notified in 2010 – incidence of 462/100,000 pop Approx 48% of pulmonary.
Optimization of Sputum Smear for Detection of TB: A Prospective Blinded Evaluation Joy Sarojini Michael, Kalaiselvan S, Peter Daley, Lois Armstrong, Shalini.
Etiology of Illness in Patients with Severe Sepsis Admitted to the Hospital from the Emergency Department Alan C. Heffner,1,3 James M. Horton,2 Michael.
Health economics of workplace HIV programmes A cost benefit analysis of Anglo Coal’s ART programme Gesine Meyer-Rath 1,2,3, Jan Pienaar 4, Brian Brink.
#AIDS2016 Intensified TB case-finding among PLHIV: diagnostic yield of Xpert MTB/RIF, Determine TB-LAM and liquid culture Fred Semitala,
Boston University Slideshow Title Goes Here Eliminating CD4 thresholds in South Africa will not lead to large increases in persons receiving ART without.
New WHO algorithm to prevent TB deaths in seriously ill patients with HIV Yohhei Hamada TB/HIV and Community Engagement.
Amir Shroufi Medical Coordinator MSF South Africa
The role of secondary prophylaxis in the management of HIV-VL co-infection: 7-years experience from West Bengal Prof. Rama Prosad Goswami, Department.
World Health Organization
Addressing the challenges and successes of expediting TB treatment among PLHIV who are seriously ill: experience from Kenya Masini E & Olwande C National.
Participants 18year old+
Charles D. Wells, MD Chief, International Research and Programs Branch
LAM assay: overview and practical guidance on its adoption and use
Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV- associated pulmonary tuberculosis before antiretroviral therapy:
Meningitis Surveillance and investigation of causes of altered mental status among Kamuzu Central Hospital admissions, Lilongwe, Malawi Charles Kyriakos.
HIV-associated TB mortality and blocks in the cascade
PRIORITIZING TB in 2018 PEPFAR COPS
The use of cotrimoxazole prophylaxis in the context of HIV infection
Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV- associated pulmonary tuberculosis before antiretroviral therapy:
Blood Culture (Bacterial, Mycobacterial & Fungal)
PCP: management of co-infection
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
Tuberculosis Global Epidemiology
PCP: management of co-infection
When to START During an OI
Ordering Sputum Cultures in Community Acquired Pneumonia
Volume 392, Issue 10144, Pages (July 2018)
Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study  Krishna P Reddy,
5th edition NTP MANUAL OF PROCEDURES Case Finding
TB Screening and Differentiated Service Delivery: State of the Art
Mapping of LF-LAM Uptake with Global Fund & PEPFAR Funding
Presentation transcript:

Evidence for use of urinary LAM Dr Tom Boyles University of the Witwatersrand, Johannesburg, South Africa With thanks to Ankur Gupta-Wright for slides from STAMP trial The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

Conflicts of interest Alere now Abbott- Speaker fees for academic meetings Donation of LAM strips Lending of equipment for studies The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

Significant morbidity and mortality from HIV/TB 0.4 million deaths in 20161 TB causes 32-67% deaths in HIV+ adults admitted to hospital in Africa2 Half undiagnosed at time of death2 Urine-diagnostics have good diagnostic yield3 Urine easily obtained Disseminated TB common in advanced HIV Global Tuberculosis Report 2017 Gupta et al, AIDS 2015. Systematic Review and Meta-Analysis of PM studies Lawn et al, BMC Med 2015 & BMC Med 2017. Observational study The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

We don’t do If no one does it skip The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

Costs and training Costs Cost savings Training $3 per test Less other investigations e.g. ultrasound scans Training Debate regarding use at bedside or by referral to laboratory services The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

How to test a test Diagnostic intervention research Test research Diagnostic research Diagnostic intervention research The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

P = Adults suspected of having TB I = Urine LAM C = Xpert/nothing O = Morbidity and mortality The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

Pooled sensitivity 44% Pooled specificity 92% All patients with HIV Pooled sensitivity 44% Pooled specificity 92% The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

Pooled sensitivity 54% Pooled specificity 90% Inpatients with HIV Pooled sensitivity 54% Pooled specificity 90% The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

Pooled sensitivity 21% Pooled specificity 97% Outpatients with HIV Pooled sensitivity 21% Pooled specificity 97% The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

Pooled sensitivity 49% Pooled specificity 90% CD4 <200 Pooled sensitivity 49% Pooled specificity 90% The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

Pooled sensitivity 56% Pooled specificity 90% CD4 <100 Pooled sensitivity 56% Pooled specificity 90% The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

A note on specificity Possible cross reactivity with NTM Higher specificity with more reference samples and composite reference standards Nel 19/21 patients with confirmed NTM but no evidence of TB were LAM +ve Low cross reactivity found in patients with CF who had NTM of the lung Lawn >99% specificity when using multiple samples and composite reference standard Nel et al CID 2017 Lawn et al BMC Med 2017 The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

Current WHO guidance 1- LAM not to be used except as below 2- LAM may be use in HIV positive adult inpatients with Signs and symptoms of TB with CD4 count <100 If seriously ill regardless of CD4 count With unknown CD4 count (conditional recommendation, low quality evidence) WHO consolidated guideline 2016 The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

What’s new since 2016 ? Nel 19/21 patients with confirmed NTM but no evidence of TB were LAM +ve Low cross reactivity found in patients with CF who had NTM of the lung Lawn >99% specificity when using multiple samples and composite reference standard The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

We identified 10 studies eligible for inclusion in this systematic review, reporting on a total of 1172 HIV-TB cases. Of these, 512 patients (44 %) tested positive for urinary LAM Detectable LAM in the urine is an independent risk factor for mortality among patients receiving treatment for HIV-TB. The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

How to test a test Diagnostic intervention research Test research Diagnostic research Diagnostic intervention research The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

Patients with HIV needing admission Randomised to routine diagnostics +/- LAM 2500 patients in 4 countries Median CD4– 84 Primary outcomes = 8 week mortality The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

NNT 25 The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

on behalf of the STAMP trial team Rapid urine-based screening for TB to reduce AIDS-related mortality in hospitalized patients in Africa (STAMP) trial Ankur Gupta-Wright, Elizabeth L Corbett, Joep J van Oosterhout, Doug Wilson, Daniel Grint, Melanie Alufandika, Jurgens A Peters, Lingstone Chiume, Stephen D Lawn & Katherine Fielding on behalf of the STAMP trial team CROI 2018 The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

2600 UNSELECTED adult HIV+ admissions Edendale, KZN, South Africa 2600 UNSELECTED adult HIV+ admissions Irrespective of TB symptoms Exclude: <18 years old TB treatment in last 12 months IPT in last 6 months Outside follow-up area Admitted >48 hours Unable to provide consent Zomba, Malawi Standard of care arm Sputum Xpert MTB/RIF Intervention arm Sputum Xpert MTB/RIF + Urine TB-LAM and Xpert MTB/RIF + CROI 2018 The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

Unselected HIV +ve admissions 90% at least 1 TB symptom 85% on ART CD4 215 11.5% had TB CROI 2018 The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

CROI 2018 The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

Microbiologically confirmed TB, intervention arm (n=210) Samples submitted for TB testing: 99.0% produced urine 56.9% produced sputum 14.3% (n=30) Sputum Xpert (n=85) 8.6% (n=18) 13.8% (n=29) 3.8% (n=8) 41.4% (n=87) Urine LAM (n=158) 6.2% (n=13) 11.4% (n=24) Urine Xpert (n= 74) Note: 1 patient was negative on all Xpert and LAM tests but was sputum TB culture positive The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

Diagnostic accuracy, incremental yield and cost of determine TB-LAM and sputum induction for in seriously ill adults with HIV, cough and WHO danger signs Tom H Boyles1, Rulan Griesel2, Annemie Stewart2, Marc Mendelson1, Gary Maartens2 1Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town, South Africa 2 Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

Cough and WHO danger signs CD4 107 50% had TB 325 HIV +ve admissions Cough and WHO danger signs CD4 107 50% had TB The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

$50 $42 The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018

Summary Cheap Point of care Identifies sick patients with TB 2 RCTs show mortality benefit May be cost saving The Global Action Fund for Fungal Infections meeting Kampala 10-12 April 2018